{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:00:18Z","timestamp":1790265618646,"version":"4.1.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The mesenchymal-epithelial transition factor (c-MET) is an emerging target for molecular imaging owing to its widespread overexpression across multiple cancer types. This systematic review evaluated radioactive and fluorescent c-MET-targeting tracers in preclinical and clinical studies, focussing on their translational potential and imaging performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review was conducted according to PRISMA 2020 guidelines. A PubMed, Embase, and Scopus search for studies evaluating radioactive or fluorescent c-MET-targeting tracers was complemented with expert-suggested reports. Tracer characteristics, imaging performance, and safety data were extracted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty preclinical and thirteen clinical reports were included, comprising 62 distinct c-MET-targeting tracers across several compound classes. Only four peptide-based tracers progressed to clinical evaluation: the fluorescent tracers EMI-137 and cMBP-ICG, and the PET tracers \u2076\u2078Ga-EMP-100 and \u2076\u2078Ga-MetP. EMI-137 (8 studies) enabled fluorescence-guided tumour visualisation (tumour-to-background ratios; TBRs 1.3\u20139.7) and identified additional malignant lesions in selected applications. Although tracer uptake generally corresponded with c-MET expression, diagnostic performance was limited by uptake in benign c-MET-expressing tissues, yielding a sample-size weighted average sensitivity and specificity of 81.7% and 39.3%. cMBP-ICG (2 studies), evaluated exclusively in oral cavity cancer, demonstrated improved discrimination between malignant and benign tissue and outperformed conventional assessment for biopsy-site selection, reporting TBRs of 2.7\u20134.1 and a weighted average sensitivity and specificity of 85.5% and 91.1%. The PET tracers \u2076\u2078Ga-EMP-100 (2 studies) and \u2076\u2078Ga-MetP (1 study) demonstrated feasibility for whole-body c-MET PET imaging, with the latter additionally showing a positive correlation between tumour uptake and immunohistochemical c-MET expression. All four tracers showed favourable safety, with only mild adverse events reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusiontargeting tracer pipeline. Numbers represent distinct<\/jats:title>\n                    <jats:p>Despite extensive preclinical development, only four peptide-based tracers have progressed to clinical evaluation. Clinical evidence supports the feasibility of c-MET-targeted molecular imaging but remains limited by methodological heterogeneity, small sample sizes, limited biological validation, and variable diagnostic performance. Larger, standardised studies are needed to establish the added clinical value and broader applicability of c-MET-targeting tracers in molecular imaging.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08174-w","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:52:57Z","timestamp":1790218377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular imaging tracers targeting c-MET: a systematic review of preclinical evidence and clinical translation"],"prefix":"10.1007","author":[{"given":"Rick W. A.","family":"Verdijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevie M.","family":"van der Mierde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliia","family":"Berehova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten P.","family":"van Meerbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar R.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fijs W. B.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-6895","authenticated-orcid":false,"given":"Tessa","family":"Buckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"4","key":"8174_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271\u201389. https:\/\/doi.org\/10.3322\/caac.21349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"8174_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrclinonc.2014.191","volume":"12","author":"L Wyld","year":"2015","unstructured":"Wyld L, Audisio RA, Poston GJ. The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol. 2015;12(2):115\u201324. https:\/\/doi.org\/10.1038\/nrclinonc.2014.191.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"8174_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23403-5","volume":"8","author":"RK Orosco","year":"2018","unstructured":"Orosco RK, Tapia VJ, Califano JA, Clary B, Cohen EEW, Kane C, et al. Positive surgical margins in the 10 most common solid cancers. Sci Rep. 2018;8(1):5686. https:\/\/doi.org\/10.1038\/s41598-018-23403-5.","journal-title":"Sci Rep"},{"issue":"3","key":"8174_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1412","volume":"10","author":"KR Tringale","year":"2018","unstructured":"Tringale KR, Pang J, Nguyen QT. Image-guided surgery in cancer: A strategy to reduce incidence of positive surgical margins. Wiley Interdiscip Rev Syst Biol Med. 2018;10(3):e1412. https:\/\/doi.org\/10.1002\/wsbm.1412.","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"2","key":"8174_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.athoracsur.2014.09.033","volume":"99","author":"JG Hancock","year":"2015","unstructured":"Hancock JG, Rosen JE, Antonicelli A, Moreno A, Kim AW, Detterbeck FC, et al. Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery. Ann Thorac Surg. 2015;99(2):406\u201313. https:\/\/doi.org\/10.1016\/j.athoracsur.2014.09.033.","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"8174_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.eururo.2011.11.028","volume":"61","author":"M Marszalek","year":"2012","unstructured":"Marszalek M, Carini M, Chlosta P, Jeschke K, Kirkali Z, Kn\u00fcchel R, et al. Positive surgical margins after nephron-sparing surgery. Eur Urol. 2012;61(4):757\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2011.11.028.","journal-title":"Eur Urol"},{"issue":"3","key":"8174_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1245\/s10434-014-3480-5","volume":"21","author":"N Houssami","year":"2014","unstructured":"Houssami N, Macaskill P, Marinovich ML, Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol. 2014;21(3):717\u201330. https:\/\/doi.org\/10.1245\/s10434-014-3480-5.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"8174_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.eururo.2013.11.018","volume":"66","author":"P Sooriakumaran","year":"2014","unstructured":"Sooriakumaran P, Srivastava A, Shariat SF, Stricker PD, Ahlering T, Eden CG, et al. A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients. Eur Urol. 2014;66(3):450\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2013.11.018.","journal-title":"Eur Urol"},{"issue":"2","key":"8174_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/sla.0000000000001963","volume":"265","author":"C Simillis","year":"2017","unstructured":"Simillis C, Baird DL, Kontovounisios C, Pawa N, Brown G, Rasheed S, et al. A Systematic Review to Assess Resection Margin Status After Abdominoperineal Excision and Pelvic Exenteration for Rectal Cancer. Ann Surg. 2017;265(2):291\u20139. https:\/\/doi.org\/10.1097\/sla.0000000000001963.","journal-title":"Ann Surg"},{"issue":"2","key":"8174_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ygyno.2019.05.010","volume":"154","author":"NC Te Grootenhuis","year":"2019","unstructured":"Te Grootenhuis NC, Pouwer AW, de Bock GH, Hollema H, Bulten J, van der Zee AGJ, et al. Margin status revisited in vulvar squamous cell carcinoma. Gynecol Oncol. 2019;154(2):266\u201375. https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.010.","journal-title":"Gynecol Oncol"},{"issue":"Suppl 1","key":"8174_CR11","doi-asserted-by":"publisher","first-page":"E2197","DOI":"10.1002\/hed.24075","volume":"38","author":"RW Smits","year":"2016","unstructured":"Smits RW, Koljenovi\u0107 S, Hardillo JA, Ten Hove I, Meeuwis CA, Sewnaik A, et al. Resection margins in oral cancer surgery: Room for improvement. Head Neck. 2016;38(Suppl 1):E2197\u2013203. https:\/\/doi.org\/10.1002\/hed.24075.","journal-title":"Head Neck"},{"issue":"1","key":"8174_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40644-022-00482-2","volume":"22","author":"I Boekestijn","year":"2022","unstructured":"Boekestijn I, van Oosterom MN, Dell\u2019Oglio P, van Velden FHP, Pool M, Maurer T, et al. The current status and future prospects for molecular imaging-guided precision surgery. Cancer Imaging. 2022;22(1):48. https:\/\/doi.org\/10.1186\/s40644-022-00482-2.","journal-title":"Cancer Imaging"},{"key":"8174_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14212459","author":"M Malik","year":"2024","unstructured":"Malik M, Alqahtani MM, Hadadi I, Kanbayti I, Alawaji Z, Aloufi BA. Molecular imaging biomarkers for early cancer detection: a systematic review of emerging technologies and clinical applications. Diagnostics (Basel). 2024. https:\/\/doi.org\/10.3390\/diagnostics14212459.","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"8174_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/s1470-2045(19)30317-1","volume":"20","author":"S Hernot","year":"2019","unstructured":"Hernot S, van Manen L, Debie P, Mieog JSD, Vahrmeijer AL. Latest developments in molecular tracers for fluorescence image-guided cancer surgery. Lancet Oncol. 2019;20(7):354\u201367. https:\/\/doi.org\/10.1016\/s1470-2045(19)30317-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"8174_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.23736\/s1824-4785.21.03286-6","volume":"65","author":"DD Rietbergen","year":"2021","unstructured":"Rietbergen DD, van Oosterom MN, Kleinjan GH, Brouwer OR, Valdes-Olmos RA, van Leeuwen FWB, et al. Interventional nuclear medicine: a focus on radioguided intervention and surgery. Q J Nucl Med Mol Imaging. 2021;65(1):4\u201319. https:\/\/doi.org\/10.23736\/s1824-4785.21.03286-6.","journal-title":"Q J Nucl Med Mol Imaging."},{"issue":"1 Suppl","key":"8174_CR16","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1177\/1758834011422556","volume":"3","author":"SL Organ","year":"2011","unstructured":"Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(1 Suppl):S7-s19. https:\/\/doi.org\/10.1177\/1758834011422556.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"8174_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/biomedicines3010046","volume":"3","author":"G Viticchi\u00e8","year":"2015","unstructured":"Viticchi\u00e8 G, Muller PAJ. c-Met and Other Cell Surface Molecules: Interaction. Activ Funct Consequences Biomed. 2015;3(1):46\u201370. https:\/\/doi.org\/10.3390\/biomedicines3010046.","journal-title":"Activ Funct Consequences Biomed"},{"issue":"1","key":"8174_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-022-01503-1","volume":"21","author":"S Raj","year":"2022","unstructured":"Raj S, Kesari KK, Kumar A, Rathi B, Sharma A, Gupta PK, et al. Molecular mechanism(s) of regulation(s) of c-MET\/HGF signaling in head and neck cancer. Mol Cancer. 2022;21(1):31. https:\/\/doi.org\/10.1186\/s12943-022-01503-1.","journal-title":"Mol Cancer"},{"issue":"6220","key":"8174_CR19","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. https:\/\/doi.org\/10.1126\/science.1260419.","journal-title":"Science"},{"key":"8174_CR20","first-page":"195","volume":"24","author":"T Nakamura","year":"1994","unstructured":"Nakamura T. Hepatocyte growth factor as mitogen, motogen and morphogen, and its roles in organ regeneration. Princess Takamatsu Symp. 1994;24:195\u2013213.","journal-title":"Princess Takamatsu Symp"},{"issue":"12","key":"8174_CR21","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/s1357-2725(99)00089-8","volume":"31","author":"MC Stella","year":"1999","unstructured":"Stella MC, Comoglio PM. HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol. 1999;31(12):1357\u201362. https:\/\/doi.org\/10.1016\/s1357-2725(99)00089-8.","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"8174_CR22","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1158\/1078-0432.Ccr-05-1864","volume":"12","author":"MS Lyall","year":"2006","unstructured":"Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res. 2006;12(4):1184\u201391. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-05-1864.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"8174_CR23","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/sj.onc.1209859","volume":"26","author":"A Rasola","year":"2007","unstructured":"Rasola A, Fassetta M, De Bacco F, D\u2019Alessandro L, Gramaglia D, Di Renzo MF, et al. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene. 2007;26(7):1078\u201387. https:\/\/doi.org\/10.1038\/sj.onc.1209859.","journal-title":"Oncogene"},{"issue":"3","key":"8174_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.clcc.2018.02.013","volume":"17","author":"SJ Lee","year":"2018","unstructured":"Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, et al. c-MET overexpression in colorectal cancer: a poor prognostic factor for survival. Clin Colorectal Cancer. 2018;17(3):165\u20139. https:\/\/doi.org\/10.1016\/j.clcc.2018.02.013.","journal-title":"Clin Colorectal Cancer"},{"issue":"12","key":"8174_CR25","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.3748\/wjg.v21.i12.3706","volume":"21","author":"Y Liu","year":"2015","unstructured":"Liu Y, Yu XF, Zou J, Luo ZH. Prognostic value of c-Met in colorectal cancer: a meta-analysis. World J Gastroenterol. 2015;21(12):3706\u201310. https:\/\/doi.org\/10.3748\/wjg.v21.i12.3706.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"8174_CR26","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1200\/jco.2008.19.1635","volume":"27","author":"F Cappuzzo","year":"2009","unstructured":"Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009;27(10):1667\u201374. https:\/\/doi.org\/10.1200\/jco.2008.19.1635.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8174_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/annonc\/mds463","volume":"24","author":"GT Gibney","year":"2013","unstructured":"Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013;24(2):343\u20139. https:\/\/doi.org\/10.1093\/annonc\/mds463.","journal-title":"Ann Oncol"},{"issue":"4","key":"8174_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.prp.2013.02.002","volume":"209","author":"S Gunia","year":"2013","unstructured":"Gunia S, Erbersdobler A, Hakenberg OW, Koch S, May M. C-MET is expressed in the majority of penile squamous cell carcinomas and correlates with polysomy-7 but is not associated with MET oncogene amplification, pertinent histopathologic parameters, or with cancer-specific survival. Pathol Res Pract. 2013;209(4):215\u201320. https:\/\/doi.org\/10.1016\/j.prp.2013.02.002.","journal-title":"Pathol Res Pract"},{"issue":"12","key":"8174_CR29","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1002\/hed.21383","volume":"32","author":"CH Kim","year":"2010","unstructured":"Kim CH, Koh YW, Han JH, Kim JW, Lee JS, Baek SJ, et al. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck. 2010;32(12):1655\u201364. https:\/\/doi.org\/10.1002\/hed.21383.","journal-title":"Head Neck"},{"issue":"24","key":"8174_CR30","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1200\/jco.2010.34.0570","volume":"29","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011;29(24):3307\u201315. https:\/\/doi.org\/10.1200\/jco.2010.34.0570.","journal-title":"J Clin Oncol"},{"key":"8174_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071683","author":"A Thomas","year":"2022","unstructured":"Thomas A, Slade KS, Blaheta RA, Markowitsch SD, Stenzel P, Tagscherer KE, et al. Value of c-MET and associated signaling elements for predicting outcomes and targeted therapy in penile cancer. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14071683.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"8174_CR32","first-page":"5179","volume":"33","author":"SJ Lee","year":"2013","unstructured":"Lee SJ, Lee J, Sohn I, Mao M, Kai W, Park CK, et al. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res. 2013;33(11):5179\u201386.","journal-title":"Anticancer Res"},{"key":"8174_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-015-0296-y","volume":"10","author":"S Yan","year":"2015","unstructured":"Yan S, Jiao X, Zou H, Li K. Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases. Diagn Pathol. 2015;10:62. https:\/\/doi.org\/10.1186\/s13000-015-0296-y.","journal-title":"Diagn Pathol"},{"key":"8174_CR34","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.2147\/ott.S197540","volume":"12","author":"X Xu","year":"2019","unstructured":"Xu X, Zhang G, He L, Zhu Y. Clinicopathological impacts of c-Met overexpression in bladder cancer: evidence from 1,336 cases. Onco Targets Ther. 2019;12:2695\u2013702. https:\/\/doi.org\/10.2147\/ott.S197540.","journal-title":"Onco Targets Ther"},{"issue":"1 Suppl","key":"8174_CR35","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1177\/1758834011422557","volume":"3","author":"JR Sierra","year":"2011","unstructured":"Sierra JR, Tsao MS. C-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3(1 Suppl):S21-35. https:\/\/doi.org\/10.1177\/1758834011422557.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"8174_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10585-005-1617-4","volume":"21","author":"Z Zeng","year":"2004","unstructured":"Zeng Z, Weiser MR, D\u2019Alessio M, Grace A, Shia J, Paty PB. Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer. Clin Exp Metastasis. 2004;21(5):409\u201317. https:\/\/doi.org\/10.1007\/s10585-005-1617-4.","journal-title":"Clin Exp Metastasis"},{"issue":"12","key":"8174_CR37","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00259-024-06789-5","volume":"51","author":"L Quarta","year":"2024","unstructured":"Quarta L, Mazzone E, Cannoletta D, Stabile A, Scuderi S, Barletta F, et al. Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [(99m)Tc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study. Eur J Nucl Med Mol Imaging. 2024;51(12):3789\u201398. https:\/\/doi.org\/10.1007\/s00259-024-06789-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"8174_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11307-022-01736-y","volume":"25","author":"S Azargoshasb","year":"2023","unstructured":"Azargoshasb S, Boekestijn I, Roestenberg M, KleinJan GH, van der Hage JA, van der Poel HG, et al. Quantifying the impact of signal-to-background ratios on surgical discrimination of fluorescent lesions. Mol Imaging Biol. 2023;25(1):180\u20139. https:\/\/doi.org\/10.1007\/s11307-022-01736-y.","journal-title":"Mol Imaging Biol"},{"issue":"68","key":"8174_CR39","doi-asserted-by":"publisher","first-page":"113120","DOI":"10.18632\/oncotarget.21303","volume":"8","author":"JH Kim","year":"2017","unstructured":"Kim JH, Kim BJ, Kim HS. Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review. Oncotarget. 2017;8(68):113120\u20138. https:\/\/doi.org\/10.18632\/oncotarget.21303.","journal-title":"Oncotarget"},{"issue":"1","key":"8174_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00428-017-2131-1","volume":"471","author":"W Sterlacci","year":"2017","unstructured":"Sterlacci W, Fiegl M, Gugger M, Bubendorf L, Savic S, Tzankov A. MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC. Virchows Arch. 2017;471(1):49\u201355. https:\/\/doi.org\/10.1007\/s00428-017-2131-1.","journal-title":"Virchows Arch"},{"issue":"1","key":"8174_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0022-5347(05)64830-6","volume":"168","author":"P Sweeney","year":"2002","unstructured":"Sweeney P, El-Naggar AK, Lin SH, Pisters LL. Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol. 2002;168(1):51\u20135.","journal-title":"J Urol"},{"key":"8174_CR42","doi-asserted-by":"publisher","first-page":"8239","DOI":"10.12659\/msm.913514","volume":"24","author":"L Jia","year":"2018","unstructured":"Jia L, Yang X, Tian W, Guo S, Huang W, Zhao W. Increased expression of c-Met is associated with chemotherapy-resistant breast cancer and poor clinical outcome. Med Sci Monit. 2018;24:8239\u201349. https:\/\/doi.org\/10.12659\/msm.913514.","journal-title":"Med Sci Monit"},{"key":"8174_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"1","key":"8174_CR44","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"8174_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57050503","author":"TF Monaghan","year":"2021","unstructured":"Monaghan TF, Rahman SN, Agudelo CW, Wein AJ, Lazar JM, Everaert K, et al. Foundational statistical principles in medical research: sensitivity, specificity, positive predictive value, and negative predictive value. Medicina (Kaunas). 2021. https:\/\/doi.org\/10.3390\/medicina57050503.","journal-title":"Medicina (Kaunas)"},{"key":"8174_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"2","key":"8174_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00259-020-04978-6","volume":"48","author":"A Cavaliere","year":"2021","unstructured":"Cavaliere A, Sun S, Lee S, Bodner J, Li Z, Huang Y, et al. Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):383\u201394. https:\/\/doi.org\/10.1007\/s00259-020-04978-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"8174_CR48","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.2967\/jnumed.111.102293","volume":"53","author":"EM Jagoda","year":"2012","unstructured":"Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, et al. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. J Nucl Med. 2012;53(10):1592\u2013600. https:\/\/doi.org\/10.2967\/jnumed.111.102293.","journal-title":"J Nucl Med"},{"issue":"6","key":"8174_CR49","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1021\/acs.bioconjchem.9b00342","volume":"30","author":"R Fay","year":"2019","unstructured":"Fay R, Gut M, Holland JP. Photoradiosynthesis of 68Ga-labeled HBED-CC-azepin-MetMAb for immuno-PET of c-MET receptors. Bioconjug Chem. 2019;30(6):1814\u201320. https:\/\/doi.org\/10.1021\/acs.bioconjchem.9b00342.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"8174_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.7150\/thno.37098","volume":"10","author":"FE Escorcia","year":"2020","unstructured":"Escorcia FE, Houghton JL, Abdel-Atti D, Pereira PR, Cho A, Gutsche NT, et al. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors. Theranostics. 2020;10(1):151\u201365. https:\/\/doi.org\/10.7150\/thno.37098.","journal-title":"Theranostics"},{"issue":"43","key":"8174_CR51","doi-asserted-by":"publisher","first-page":"12713","DOI":"10.1039\/d2sc03928a","volume":"13","author":"F d'Orchymont","year":"2022","unstructured":"d\u2019Orchymont F, Holland JP. A rotaxane-based platform for tailoring the pharmacokinetics of cancer-targeted radiotracers. Chem sci. 2022;13(43):12713\u201325. https:\/\/doi.org\/10.1039\/d2sc03928a.","journal-title":"Chem sci"},{"issue":"8","key":"8174_CR52","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s00259-017-3672-x","volume":"44","author":"M Pool","year":"2017","unstructured":"Pool M, Terwisscha van Scheltinga AGT, Kol A, Giesen D, de Vries EGE, Lub-de Hooge MN. 89Zr-Onartuzumab PET imaging of c-MET receptor dynamics. Eur J Nucl Med Mol Imaging. 2017;44(8):1328\u201336. https:\/\/doi.org\/10.1007\/s00259-017-3672-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"8174_CR53","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2967\/jnumed.120.244897","volume":"62","author":"PMR Pereira","year":"2021","unstructured":"Pereira PMR, Norfleet J, Lewis JS, Escorcia FE. Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition. J Nucl Med. 2021;62(3):366\u201371. https:\/\/doi.org\/10.2967\/jnumed.120.244897.","journal-title":"J Nucl Med"},{"issue":"7","key":"8174_CR54","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.2967\/jnumed.119.237180","volume":"61","author":"S Klingler","year":"2020","unstructured":"Klingler S, Fay R, Holland JP. Light-Induced Radiosynthesis of 89Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor. J Nucl Med. 2020;61(7):1072\u20138. https:\/\/doi.org\/10.2967\/jnumed.119.237180.","journal-title":"J Nucl Med"},{"issue":"5","key":"8174_CR55","doi-asserted-by":"publisher","first-page":"758","DOI":"10.2967\/jnumed.115.154690","volume":"56","author":"H Luo","year":"2015","unstructured":"Luo H, Hong H, Slater MR, Graves SA, Shi S, Yang Y, et al. PET of c-Met in cancer with 64Cu-labeled hepatocyte growth factor. J Nucl Med. 2015;56(5):758\u201363. https:\/\/doi.org\/10.2967\/jnumed.115.154690.","journal-title":"J Nucl Med"},{"key":"8174_CR56","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c01344","author":"X Liu","year":"2025","unstructured":"Liu X, Chen Y, Zhang F, Qiu F, Xu X, Zhang J, et al. Preclinical evaluation of 68Ga-labeled SL1 aptamer for c-Met targeted PET imaging. Mol Pharm. 2025. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c01344.","journal-title":"Mol Pharm"},{"issue":"1","key":"8174_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1162\/15353500200200006","volume":"1","author":"RV Hay","year":"2002","unstructured":"Hay RV, Cao B, Skinner RS, Wang L-M, Su Y, Resau JH, et al. Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor\/scatter factor. Mol Imaging. 2002;1(1):56\u201362. https:\/\/doi.org\/10.1162\/15353500200200006.","journal-title":"Mol Imaging"},{"issue":"10 Pt 2","key":"8174_CR58","first-page":"3839S","volume":"9","author":"RV Hay","year":"2003","unstructured":"Hay RV, Cao B, Skinner RS, Wang L-M, Su Y, Resau JH, et al. Radioimmunoscintigraphy of human met-expressing tumor xenografts using met3, a new monoclonal antibody. Clin Cancer Res. 2003;9(10 Pt 2):3839S-S3844.","journal-title":"Clin Cancer Res"},{"issue":"19 Pt 2","key":"8174_CR59","doi-asserted-by":"publisher","first-page":"7064s","DOI":"10.1158\/1078-0432.Ccr-1004-0014","volume":"11","author":"RV Hay","year":"2005","unstructured":"Hay RV, Cao B, Skinner RS, Su Y, Zhao P, Gustafson MF, et al. Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clin Cancer Res. 2005;11(19 Pt 2):7064s-s7069. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-1004-0014.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8174_CR60","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1021\/acs.bioconjchem.4c00019","volume":"35","author":"NY Luo","year":"2024","unstructured":"Luo NY, Minne RL, Gallant JP, Gunaratne GS, West JL, Javeri S, et al. Development of an engineered single-domain antibody for targeting MET in non-small cell lung cancer. Bioconjug Chem. 2024;35(3):389\u201399. https:\/\/doi.org\/10.1021\/acs.bioconjchem.4c00019.","journal-title":"Bioconjug Chem"},{"issue":"12","key":"8174_CR61","doi-asserted-by":"publisher","first-page":"6376","DOI":"10.1021\/acs.molpharmaceut.4c00938","volume":"21","author":"RL Minne","year":"2024","unstructured":"Minne RL, Luo NY, Mork CM, Wopat MR, Esbona K, Javeri S, et al. Evaluation of a Novel MET-targeting camelid-derived antibody in head and neck cancer. Mol Pharm. 2024;21(12):6376\u201384. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00938.","journal-title":"Mol Pharm"},{"issue":"4","key":"8174_CR62","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2967\/jnumed.113.124941","volume":"55","author":"AGT Terwisscha van Scheltinga","year":"2014","unstructured":"Terwisscha van Scheltinga AGT, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hulsmeyer M, et al. In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer. J Nucl Med. 2014;55(4):665\u201371. https:\/\/doi.org\/10.2967\/jnumed.113.124941.","journal-title":"J Nucl Med"},{"issue":"11","key":"8174_CR63","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1158\/1535-7163.Mct-14-0363","volume":"13","author":"K Li","year":"2014","unstructured":"Li K, Tavare R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, et al. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther. 2014;13(11):2607\u201317. https:\/\/doi.org\/10.1158\/1535-7163.Mct-14-0363.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"8174_CR64","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00259-008-0774-5","volume":"35","author":"LR Perk","year":"2008","unstructured":"Perk LR, Stigter-van Walsum M, Visser GWM, Kloet RW, Vosjan MJWD, Leemans CR, et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008;35(10):1857\u201367. https:\/\/doi.org\/10.1007\/s00259-008-0774-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"8174_CR65","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1158\/1535-7163.Mct-11-0891","volume":"11","author":"MJWD Vosjan","year":"2012","unstructured":"Vosjan MJWD, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GAMS. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther. 2012;11(4):1017\u201325. https:\/\/doi.org\/10.1158\/1535-7163.Mct-11-0891.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"8174_CR66","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s00259-023-06495-8","volume":"51","author":"L Bu","year":"2024","unstructured":"Bu L, Ma X, Ji A, Geng K, Feng H, Li L, et al. Development of a novel 18F-labeled small molecule probe for PET imaging of mesenchymal epithelial transition receptor expression. Eur J Nucl Med Mol Imaging. 2024;51(3):656\u201368. https:\/\/doi.org\/10.1007\/s00259-023-06495-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"8174_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2026.103711","volume":"21","author":"SPL Saw","year":"2026","unstructured":"Saw SPL, Li MSC, Park S, Hatano H, Uehara Y, Menis J, et al. Targeting MET in EGFR-mutated NSCLC. J Thorac Oncol. 2026;21(7):103711. https:\/\/doi.org\/10.1016\/j.jtho.2026.103711.","journal-title":"J Thorac Oncol"},{"key":"8174_CR68","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.nucmedbio.2020.12.002","volume":"93","author":"VT Lien","year":"2021","unstructured":"Lien VT, Celen S, Nuruddin S, Attili B, Doumont G, Van Simaeys G, et al. Preclinical evaluation of [18F]cabozantinib as a PET imaging agent in a prostate cancer mouse model. Nucl Med Biol. 2021;93:74\u201380. https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.12.002.","journal-title":"Nucl Med Biol"},{"issue":"10","key":"8174_CR69","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1007\/s00259-024-06791-x","volume":"51","author":"T Buckle","year":"2024","unstructured":"Buckle T, Rietbergen DDD, de Wit-van der Veen L, Schottelius M. Lessons learned in application driven imaging agent design for image-guided surgery. Eur J Nucl Med Mol Imaging. 2024;51(10):3040\u201354. https:\/\/doi.org\/10.1007\/s00259-024-06791-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8174_CR70","doi-asserted-by":"publisher","DOI":"10.1097\/coc.0000000000001319","author":"X Fan","year":"2026","unstructured":"Fan X, Song Y, Liao Q, Qi J, Liu G. The landscape of clinical trials for targeting c-MET therapy. Am J Clin Oncol. 2026. https:\/\/doi.org\/10.1097\/coc.0000000000001319.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"8174_CR71","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41589-019-0285-7","volume":"15","author":"K Sakai","year":"2019","unstructured":"Sakai K, Passioura T, Sato H, Ito K, Furuhashi H, Umitsu M, et al. Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor. Nat Chem Biol. 2019;15(6):598\u2013606. https:\/\/doi.org\/10.1038\/s41589-019-0285-7.","journal-title":"Nat Chem Biol"},{"issue":"4","key":"8174_CR72","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1021\/acs.molpharmaceut.2c01020","volume":"20","author":"S Warashina","year":"2023","unstructured":"Warashina S, Sato H, Zouda M, Takahashi M, Wada Y, Passioura T, et al. Two-chain mature hepatocyte growth factor-specific positron emission tomography imaging in tumors using 64Cu-Labeled HiP-8, a nonstandard macrocyclic peptide probe. Mol Pharm. 2023;20(4):2029\u201338. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c01020.","journal-title":"Mol Pharm"},{"issue":"5","key":"8174_CR73","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2967\/jnumed.115.164384","volume":"57","author":"A Arulappu","year":"2016","unstructured":"Arulappu A, Battle M, Eisenblaetter M, McRobbie G, Khan I, Monypenny J, et al. c-Met PET imaging detects early-stage locoregional recurrence of basal-like breast cancer. J Nucl Med. 2016;57(5):765\u201370. https:\/\/doi.org\/10.2967\/jnumed.115.164384.","journal-title":"J Nucl Med"},{"key":"8174_CR74","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2310\/7290.2015.00023","volume":"14","author":"EM Jagoda","year":"2015","unstructured":"Jagoda EM, Bhattacharyya S, Kalen J, Riffle L, Leeder A, Histed S, et al. Imaging the Met receptor tyrosine kinase (Met) and assessing tumor responses to a Met tyrosine kinase inhibitor in human xenograft mouse models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) labeled peptide. Mol Imaging. 2015;14:499\u2013515.","journal-title":"Mol Imaging"},{"issue":"6","key":"8174_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199024","volume":"13","author":"W Li","year":"2018","unstructured":"Li W, Zheng H, Xu J, Cao S, Xu X, Xiao P. Imaging c-Met expression using 18F-labeled binding peptide in human cancer xenografts. PLoS ONE. 2018;13(6):e0199024. https:\/\/doi.org\/10.1371\/journal.pone.0199024.","journal-title":"PLoS ONE"},{"issue":"8","key":"8174_CR76","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1111\/j.1349-7006.2011.01983.x","volume":"102","author":"E-M Kim","year":"2011","unstructured":"Kim E-M, Jeong M-H, Kim DW, Jeong H-J, Lim ST, Sohn M-H. Iodine 125-labeled mesenchymal-epithelial transition factor binding peptide-click-cRGDyk heterodimer for glioma imaging. Cancer Sci. 2011;102(8):1516\u201321. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.01983.x.","journal-title":"Cancer Sci"},{"issue":"4","key":"8174_CR77","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.nucmedbio.2009.01.005","volume":"36","author":"E-M Kim","year":"2009","unstructured":"Kim E-M, Park E-H, Cheong S-J, Lee C-M, Kim DW, Jeong H-J, et al. Characterization, biodistribution and small-animal SPECT of I-125-labeled c-Met binding peptide in mice bearing c-Met receptor tyrosine kinase-positive tumor xenografts. Nucl Med Biol. 2009;36(4):371\u20138. https:\/\/doi.org\/10.1016\/j.nucmedbio.2009.01.005.","journal-title":"Nucl Med Biol"},{"issue":"11","key":"8174_CR78","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.2967\/jnumed.117.206730","volume":"59","author":"Z Han","year":"2018","unstructured":"Han Z, Xiao Y, Wang K, Yan J, Xiao Z, Fang F, et al. Development of a SPECT tracer to image c-Met expression in a xenograft model of non-small cell lung cancer. J Nucl Med. 2018;59(11):1686\u201391. https:\/\/doi.org\/10.2967\/jnumed.117.206730.","journal-title":"J Nucl Med"},{"issue":"22","key":"8174_CR79","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1039\/d1tb00408e","volume":"9","author":"Y Tang","year":"2021","unstructured":"Tang Y, Xu H, Dai Y, Wang F, Huang W, Liu P, et al. A novel peptide targeting c-Met for hepatocellular carcinoma diagnosis. J Mater Chem B. 2021;9(22):4577\u201386. https:\/\/doi.org\/10.1039\/d1tb00408e.","journal-title":"J Mater Chem B"},{"issue":"4","key":"8174_CR80","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/cbdd.13432","volume":"93","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Meng L, Li B, Tan H, Lin Q-Y, Cheng D, et al. Preliminary application of micro-SPECT\/CT imaging by 99m Tc-tricine-EDDA-HYNIC-c-Met for non-small-cell lung cancer. Chem Biol Drug Des. 2019;93(4):447\u201353. https:\/\/doi.org\/10.1111\/cbdd.13432.","journal-title":"Chem Biol Drug Des"},{"key":"8174_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071915","author":"JH Teh","year":"2023","unstructured":"Teh JH, Amgheib A, Fu R, Barnes C, Abrahams J, Ashek A, et al. Evaluation of [18F]AlF-EMP-105 for molecular imaging of C-Met. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15071915.","journal-title":"Pharmaceutics"},{"key":"8174_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102509","author":"JW Lee","year":"2024","unstructured":"Lee JW, Nickel KP, Minne RL, Jeffery JJ, Aluicio-Sarduy E, Kim C, et al. Multifunctional dendrimer-peptide conjugates for MET receptor-specific imaging of cancer cells. Nano Today. 2024. https:\/\/doi.org\/10.1016\/j.nantod.2024.102509.","journal-title":"Nano Today"},{"issue":"1","key":"8174_CR83","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1021\/acs.jmedchem.5c02886","volume":"69","author":"R Luo","year":"2026","unstructured":"Luo R, Sun L, Zhao X, Li Y, Tan B, Wang T, et al. Harnessing insights of hepatocyte growth factor kringle 3 domain to develop c-met targeted positron emission tomography probe. J Med Chem. 2026;69(1):488\u2013500. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02886.","journal-title":"J Med Chem"},{"issue":"7","key":"8174_CR84","doi-asserted-by":"publisher","first-page":"8168","DOI":"10.1021\/acs.jmedchem.5c03596","volume":"69","author":"Y Hu","year":"2026","unstructured":"Hu Y, Chen Y, Zhu J, Qian K, Guo D, Zeng B, et al. Synthesis, preclinical investigations, and pilot clinical imaging studies of (68)Ga-labeled peptide-derived c-Met-targeted PET probes. J Med Chem. 2026;69(7):8168\u201380. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03596.","journal-title":"J Med Chem"},{"issue":"12","key":"8174_CR85","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.7150\/thno.15718","volume":"6","author":"SA Esfahani","year":"2016","unstructured":"Esfahani SA, Heidari P, Kim SA, Ogino S, Mahmood U. Optical imaging of mesenchymal epithelial transition factor (MET) for enhanced detection and characterization of primary and metastatic hepatic tumors. Theranostics. 2016;6(12):2028\u201338. https:\/\/doi.org\/10.7150\/thno.15718.","journal-title":"Theranostics"},{"issue":"2","key":"8174_CR86","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/cncr.29029","volume":"121","author":"S Liu","year":"2015","unstructured":"Liu S, Zheng Y, Volpi D, El-Kasti M, Klotz D, Tullis I, et al. Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer. Cancer. 2015;121(2):202\u201313. https:\/\/doi.org\/10.1002\/cncr.29029.","journal-title":"Cancer"},{"issue":"1","key":"8174_CR87","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/1078-0432.Ccr-24-1522","volume":"31","author":"Y-J Huang","year":"2025","unstructured":"Huang Y-J, Rieder J, Tan KV, Tenditnaya A, Vojnovic B, Gorpas D, et al. Targeting c-MET for endoscopic detection of dysplastic lesions within Barrett\u2019s Esophagus Using EMI-137 fluorescence imaging. Clin Cancer Res. 2025;31(1):98\u2013109. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1522.","journal-title":"Clin Cancer Res"},{"key":"8174_CR88","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.canlet.2016.10.030","volume":"385","author":"DW Hwang","year":"2017","unstructured":"Hwang DW, Bahng N, Ito K, Ha S, Kim MY, Lee E, et al. In vivo targeting of c-Met using a non-standard macrocyclic peptide in gastric carcinoma. Cancer Lett. 2017;385:144\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2016.10.030.","journal-title":"Cancer Lett"},{"issue":"7","key":"8174_CR89","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/j.1349-7006.2011.01983.x","volume":"20","author":"E-M Kim","year":"2009","unstructured":"Kim E-M, Park E-H, Cheong S-J, Lee C-M, Jeong H-J, Kim DW, et al. In vivo imaging of mesenchymal-epithelial transition factor (c-Met) expression using an optical imaging system. Bioconjug Chem. 2009;20(7):1299\u2013306. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.01983.x.","journal-title":"Bioconjug Chem"},{"issue":"3","key":"8174_CR90","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1039\/d0bm01737j","volume":"9","author":"B Lin","year":"2021","unstructured":"Lin B, Wu J, Wang Y, Sun S, Yuan Y, Tao X, et al. Peptide functionalized upconversion\/NIR II luminescent nanoparticles for targeted imaging and therapy of oral squamous cell carcinoma. Biomater Sci. 2021;9(3):1000\u20137. https:\/\/doi.org\/10.1039\/d0bm01737j.","journal-title":"Biomater Sci"},{"issue":"1","key":"8174_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54385-7","volume":"9","author":"X Wu","year":"2019","unstructured":"Wu X, Zhou J, Wang F, Meng X, Chen J, Chang T-S, et al. Detection of colonic neoplasia in vivo using near-infrared-labeled peptide targeting cMet. Sci Rep. 2019;9(1):17917. https:\/\/doi.org\/10.1038\/s41598-019-54385-7.","journal-title":"Sci Rep"},{"key":"8174_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194795","author":"X Wu","year":"2023","unstructured":"Wu X, Chen C-W, Jaiswal S, Chang T-S, Zhang R, Dame MK, et al. Near-infrared imaging of colonic adenomas in vivo using orthotopic human organoids for early cancer detection. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15194795.","journal-title":"Cancers"},{"key":"8174_CR93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-4939-2272-7_3","volume":"1266","author":"NJ Yang","year":"2015","unstructured":"Yang NJ, Hinner MJ. Getting across the cell membrane: an overview for small molecules, peptides, and proteins. Methods Mol Biol. 2015;1266:29\u201353. https:\/\/doi.org\/10.1007\/978-1-4939-2272-7_3.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"8174_CR94","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1021\/jm900803q","volume":"53","author":"C Wu","year":"2010","unstructured":"Wu C, Tang Z, Fan W, Zhu W, Wang C, Somoza E, et al. In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor. J Med Chem. 2010;53(1):139\u201346. https:\/\/doi.org\/10.1021\/jm900803q.","journal-title":"J Med Chem"},{"issue":"15","key":"8174_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115577","volume":"28","author":"Q Lin","year":"2020","unstructured":"Lin Q, Zhang Y, Fu Z, Hu B, Si Z, Zhao Y, et al. Synthesis and evaluation of 18F labeled crizotinib derivative [18F]FPC as a novel PET probe for imaging c-MET-positive NSCLC tumor. Bioorg Med Chem. 2020;28(15):115577. https:\/\/doi.org\/10.1016\/j.bmc.2020.115577.","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"8174_CR96","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.1007\/s10967-024-09792-0","volume":"333","author":"J Feng","year":"2024","unstructured":"Feng J, Zhang X, Ruan Q, et al. Synthesis and bioevaluation of a novel 99mTc-labeled complex with a crizotinib HYNIC derivative for imaging of c-Met-positive expression. J Radioanal Nucl Chem. 2024;333(12):6273\u201382. https:\/\/doi.org\/10.1007\/s10967-024-09792-0.","journal-title":"J Radioanal Nucl Chem"},{"issue":"28","key":"8174_CR97","doi-asserted-by":"publisher","first-page":"33890","DOI":"10.1021\/acsami.3c05926","volume":"15","author":"Z Hu","year":"2023","unstructured":"Hu Z, Li R, Cui X, Chen Z. Albumin-based cyanine crizotinib conjugate nanoparticles for NIR-II imaging-guided synergistic chemophototherapy. ACS Appl Mater Interfaces. 2023;15(28):33890\u2013902. https:\/\/doi.org\/10.1021\/acsami.3c05926.","journal-title":"ACS Appl Mater Interfaces"},{"key":"8174_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2021.122128","volume":"226","author":"J Tao","year":"2021","unstructured":"Tao J, Tu Y, Liu P, Tang Y, Wang F, Li Z, et al. Detection of colorectal cancer using a small molecular fluorescent probe targeted against c-Met. Talanta. 2021;226:122128. https:\/\/doi.org\/10.1016\/j.talanta.2021.122128.","journal-title":"Talanta"},{"issue":"1","key":"8174_CR99","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41698-025-01144-9","volume":"9","author":"MS Tsao","year":"2025","unstructured":"Tsao MS, Sholl L, Shiller M, Illei P, Wistuba II, Beasley MB, et al. MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer. NPJ Precis Oncol. 2025;9(1):369. https:\/\/doi.org\/10.1038\/s41698-025-01144-9.","journal-title":"NPJ Precis Oncol"},{"issue":"12","key":"8174_CR100","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.humpath.2015.06.025","volume":"46","author":"C Zhu","year":"2015","unstructured":"Zhu C, Xu J, Li M, Zhao G, Cao H. Heterogeneity of c-Met expression in Chinese gastric cancer patients. Hum Pathol. 2015;46(12):1901\u20137. https:\/\/doi.org\/10.1016\/j.humpath.2015.06.025.","journal-title":"Hum Pathol"},{"issue":"20","key":"8174_CR101","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1039\/d1bm00674f","volume":"9","author":"D Li","year":"2021","unstructured":"Li D, Yang M, Liang M, Mei C, Lin Y, Yang F, et al. c-Met-targeted near-infrared fluorescent probe for real-time depiction and dissection of perineural invasion and lymph node metastasis lesions in pancreatic ductal adenocarcinoma xenograft models. Biomater sci. 2021;9(20):6737\u201352. https:\/\/doi.org\/10.1039\/d1bm00674f.","journal-title":"Biomater sci"},{"key":"8174_CR102","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2021.02.019","volume":"332","author":"M Liang","year":"2021","unstructured":"Liang M, Yang M, Wang F, Wang X, He B, Mei C, et al. Near-infrared fluorescence-guided resection of micrometastases derived from esophageal squamous cell carcinoma using a c-Met-targeted probe in a preclinical xenograft model. J Controlled Release. 2021;332:171\u201383. https:\/\/doi.org\/10.1016\/j.jconrel.2021.02.019.","journal-title":"J Controlled Release"},{"issue":"9","key":"8174_CR103","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s00259-023-06250-z","volume":"50","author":"M Liang","year":"2023","unstructured":"Liang M, Wang L, Xiao Y, Yang M, Mei C, Zhang Y, et al. Preclinical evaluation of a novel EGFR&c-Met bispecific near infrared probe for visualization of esophageal cancer and metastatic lymph nodes. Eur J Nucl Med Mol Imaging. 2023;50(9):2787\u2013801. https:\/\/doi.org\/10.1007\/s00259-023-06250-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"8174_CR104","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/nm.3641","volume":"21","author":"J Burggraaf","year":"2015","unstructured":"Burggraaf J, Kamerling IMC, Gordon PB, Schrier L, de Kam ML, Kales AJ, et al. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 2015;21(8):955\u201361. https:\/\/doi.org\/10.1038\/nm.3641.","journal-title":"Nat Med"},{"issue":"12","key":"8174_CR105","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.7150\/thno.42224","volume":"10","author":"SJ De Jongh","year":"2020","unstructured":"De Jongh SJ, Voskuil FJ, Schmidt I, Karrenbeld A, Kats-Ugurlu G, Meersma GJ, et al. C-Met targeted fluorescence molecular endoscopy in Barrett\u2019s esophagus patients and identification of outcome parameters for phase-I studies. Theranostics. 2020;10(12):5357\u201367. https:\/\/doi.org\/10.7150\/thno.42224.","journal-title":"Theranostics"},{"issue":"10","key":"8174_CR106","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2967\/jnumed.119.238790","volume":"61","author":"SJ de Jongh","year":"2020","unstructured":"de Jongh SJ, Vrouwe JPM, Voskuil FJ, Schmidt I, Westerhof J, Koornstra JJ, et al. The optimal imaging window for dysplastic colorectal polyp detection using c-Met-targeted fluorescence molecular endoscopy. J Nucl Med. 2020;61(10):1435\u201341. https:\/\/doi.org\/10.2967\/jnumed.119.238790.","journal-title":"J Nucl Med"},{"key":"8174_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112674","author":"T Buckle","year":"2021","unstructured":"Buckle T, van Alphen M, van Oosterom MN, van Beurden F, Heimburger N, van der Wal JE, et al. Translation of c-Met targeted image-guided surgery solutions in oral cavity cancer-initial proof of concept data. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13112674.","journal-title":"Cancers"},{"issue":"1","key":"8174_CR108","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2967\/jnumed.120.261864","volume":"63","author":"HMd Vries","year":"2022","unstructured":"Vries HMd, Bekers E, van Oosterom MN, Karakullukcu MB, van der Poel HG, et al. c-MET receptor-targeted fluorescence on the road to image-guided surgery in penile squamous cell carcinoma patients. J Nucl Med. 2022;63(1):51\u20136. https:\/\/doi.org\/10.2967\/jnumed.120.261864.","journal-title":"J Nucl Med."},{"issue":"10","key":"8174_CR109","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1007\/s00259-022-05763-3","volume":"49","author":"PKC Jonker","year":"2022","unstructured":"Jonker PKC, Metman MJH, Sondorp LHJ, Sywak MS, Gill AJ, Jansen L, et al. Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection. Eur J Nucl Med Mol Imaging. 2022;49(10):3557\u201370. https:\/\/doi.org\/10.1007\/s00259-022-05763-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8174_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2021.101679","volume":"40","author":"GR Armstrong","year":"2022","unstructured":"Armstrong GR, Khot MI, Portal C, West NP, Perry SL, Maisey TI, et al. A novel fluorescent c-met targeted imaging agent for intra-operative colonic tumour mapping: Translation from the laboratory into a clinical trial. Surg Oncol. 2022;40:101679. https:\/\/doi.org\/10.1016\/j.suronc.2021.101679.","journal-title":"Surg Oncol"},{"issue":"8","key":"8174_CR111","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s00259-023-06525-5","volume":"51","author":"MJH Metman","year":"2024","unstructured":"Metman MJH, Jonker PKC, Sondorp LHJ, van Hemel BM, Sywak MS, Gill AJ, et al. MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer. Eur J Nucl Med Mol Imaging. 2024;51(8):2384\u201394. https:\/\/doi.org\/10.1007\/s00259-023-06525-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"8174_CR112","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1245\/s10434-022-12532-x","volume":"30","author":"J Wang","year":"2023","unstructured":"Wang J, Li S, Wang K, Zhu L, Yang L, Zhu Y, et al. A c-MET-targeted topical fluorescent probe cMBP-ICG improves oral squamous cell carcinoma detection in humans. Ann Surg Oncol. 2023;30(1):641\u201351. https:\/\/doi.org\/10.1245\/s10434-022-12532-x.","journal-title":"Ann Surg Oncol"},{"key":"8174_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101978","author":"J Wang","year":"2025","unstructured":"Wang J, Shen X, Ma Q, Yang L, Zhou X, Wang L, et al. Near-infrared fluorescence imaging with an MET-targeting probe for biopsy site selection in patients with oral potentially malignant disorders. Cell Rep Med. 2025. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101978.","journal-title":"Cell Rep Med"},{"issue":"5","key":"8174_CR114","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00259-021-05596-6","volume":"49","author":"LM Mittlmeier","year":"2022","unstructured":"Mittlmeier LM, Todica A, Gildehaus F-J, Unterrainer M, Beyer L, Brendel M, et al. 68Ga-EMP-100 PET\/CT-a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma-first in-human biodistribution and imaging results. Eur J Nucl Med Mol Imaging. 2022;49(5):1711\u201320. https:\/\/doi.org\/10.1007\/s00259-021-05596-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"8174_CR115","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00259-022-05995-3","volume":"50","author":"LM Unterrainer","year":"2023","unstructured":"Unterrainer LM, Todica A, Beyer L, Brendel M, Holzgreve A, Kauffmann-Guerrero D, et al. (68)Ga-EMP-100 PET\/CT-a novel method for non-invasive assessment of c-MET expression in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2023;50(2):628\u20139. https:\/\/doi.org\/10.1007\/s00259-022-05995-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"8174_CR116","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","volume":"10","author":"W Xiao","year":"2025","unstructured":"Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W, et al. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther. 2025;10(1):74. https:\/\/doi.org\/10.1038\/s41392-024-02107-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"8174_CR117","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2967\/jnumed.119.228684","volume":"61","author":"FWB Van Leeuwen","year":"2020","unstructured":"Van Leeuwen FWB, Schottelius M, Brouwer OR, Vidal-Sicart S, Achilefu S, Klode J, et al. Trending: radioactive and fluorescent bimodal\/hybrid tracers as multiplexing solutions for surgical guidance. J Nucl Med. 2020;61(1):13\u20139. https:\/\/doi.org\/10.2967\/jnumed.119.228684.","journal-title":"J Nucl Med"},{"issue":"4","key":"8174_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.craph.2026.100067","volume":"19","author":"PR Kumar","year":"2026","unstructured":"Kumar PR, Sahu S, Mishra H, Gupta S, Moharana BP, Balraj C, et al. Next-generation theranostic radiopharmaceuticals: integrating alpha emitters and nanocarriers for precision oncology. Curr Radiopharm. 2026;19(4):100067. https:\/\/doi.org\/10.1016\/j.craph.2026.100067.","journal-title":"Curr Radiopharm"},{"issue":"7","key":"8174_CR119","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1021\/bc8005539","volume":"20","author":"E Kim","year":"2009","unstructured":"Kim E, Park EH, Cheong SJ, Lee CM, Jeong HJ, Kim DW, et al. In vivo imaging of mesenchymal-epithelial transition factor (c-Met) expression using an optical imaging system. Bioconjug Chem. 2009;20(7):1299\u2013306. https:\/\/doi.org\/10.1021\/bc8005539.","journal-title":"Bioconjug Chem"},{"issue":"3","key":"8174_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101983","volume":"6","author":"M Sattler","year":"2025","unstructured":"Sattler M, Salgia R. The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer. Cell Rep Med. 2025;6(3):101983. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101983.","journal-title":"Cell Rep Med"},{"issue":"24","key":"8174_CR121","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1200\/jco-25-01061","volume":"43","author":"JE Reuss","year":"2025","unstructured":"Reuss JE, Kuruvilla S, Ismaila N, Azar IH, Feldman J, Furuya N, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. J Clin Oncol. 2025;43(24):e31\u201344. https:\/\/doi.org\/10.1200\/jco-25-01061.","journal-title":"J Clin Oncol"},{"key":"8174_CR122","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf331","author":"A Syal","year":"2025","unstructured":"Syal A, Meyer ML, Angelino K, Osei N, Gomez JE, Sen T, et al. Antibody drugs conjugates in non-small cell lung cancer: current status and challenges. Oncologist. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyaf331.","journal-title":"Oncologist"},{"key":"8174_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.923260","volume":"12","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Li D, Yun H, Tong J, Liu W, Chai K, et al. Opportunities and challenges of targeting c-Met in the treatment of digestive tumors. Front Oncol. 2022;12:923260. https:\/\/doi.org\/10.3389\/fonc.2022.923260.","journal-title":"Front Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08174-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08174-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08174-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:02:56Z","timestamp":1790262176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08174-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":123,"alternative-id":["8174"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08174-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a systematic review of previously published literature and did not involve human participants or animals.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}